6-methoxy-2-methylquinazoline-4-thiol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-methoxy-2-methylquinazoline-4-thiol
• 英文别名: 6-methoxy-2-methyl-1H-quinazoline-4-thione
• 化学式: C₁₀H₁₀N₂OS
• 分子量: 206.268
• InChiKey: NZOIOMLIKSXIDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  65.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-((5-(2-bromoacetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide 、 6-methoxy-2-methylquinazoline-4-thiol 在 sodium methylate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以16.25 g的产率得到2-hydroxy-N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide
  参考文献：
  名称：

  [EN] COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS
  [FR] COMPOSÉS ET LEUR UTILISATION COMME INHIBITEURS D'HDAC6

  摘要：

  The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein Y1is a 9- or 10-membered bicyclic heteroaryl, Y2is a 5-membered heteroaryl, Z1is selected from (C=O)-R9, S(O)-R9and S(O2)-R9, L is an alkyl-, cycloalkyl- or heterocycloalkyl-based linker, and R1and R9may be various groups. The present invention further relates to a compound of formula (I) as HDAC6 inhibitor, typically for use in the treatment and/or the prevention of an HDAC6-associated disease, such as cancers, neurodegenerative diseases, neuropathies or cardiovascular diseases.

  公开号：

  WO2023118507A2
• 作为产物：
  描述：

  2-氨基-5-甲氧基苯甲酰胺 在 劳森试剂 、 sodium hydride 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 24.0h， 生成 6-methoxy-2-methylquinazoline-4-thiol
  参考文献：
  名称：

  [EN] COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS
  [FR] COMPOSÉS ET LEUR UTILISATION COMME INHIBITEURS D'HDAC6

  摘要：

  The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein Y1is a 9- or 10-membered bicyclic heteroaryl, Y2is a 5-membered heteroaryl, Z1is selected from (C=O)-R9, S(O)-R9and S(O2)-R9, L is an alkyl-, cycloalkyl- or heterocycloalkyl-based linker, and R1and R9may be various groups. The present invention further relates to a compound of formula (I) as HDAC6 inhibitor, typically for use in the treatment and/or the prevention of an HDAC6-associated disease, such as cancers, neurodegenerative diseases, neuropathies or cardiovascular diseases.

  公开号：

  WO2023118507A2

文献信息

• [EN] COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS<br/>[FR] COMPOSÉS ET LEUR UTILISATION COMME INHIBITEURS D'HDAC6
  申请人：[en]AUGUSTINE THERAPEUTICS

  公开号：WO2023118507A2

  公开（公告）日：2023-06-29

  The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein Y1is a 9- or 10-membered bicyclic heteroaryl, Y2is a 5-membered heteroaryl, Z1is selected from (C=O)-R9, S(O)-R9and S(O2)-R9, L is an alkyl-, cycloalkyl- or heterocycloalkyl-based linker, and R1and R9may be various groups. The present invention further relates to a compound of formula (I) as HDAC6 inhibitor, typically for use in the treatment and/or the prevention of an HDAC6-associated disease, such as cancers, neurodegenerative diseases, neuropathies or cardiovascular diseases.